ModeX Therapeutics

We are shaping a new and better way to make transformational medicines a reality for people in need. ModeX is an OPKO Health company (Nasdaq: OPK).

[ModeX Therapeutics @ModeXTx]

ModeX’s Dr. John Mascola will be at World Vaccine Congress 2026 to discuss the development of unique tetravalent antibodies for COVID and influenza highlighting ModeX’s work in this area. If you are at the Congress, drop in and join the conversation. @jrmascola

[ModeX Therapeutics @ModeXTx]

We are excited to announce we have
initiated Phase 1/2a clinical trial (NCT07110584) with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology and immune disorders. See here for more https://t.co/btkCURopZ2
$OPK #multispecifics #antibodies

[ModeX Therapeutics @ModeXTx]

Don’t miss ModeX Therapeutics’s poster presentation at #ESMO25 and stay at the forefront of research with multispecific antibodies. Learn more about our pipeline here:
https://t.co/vKeAg0PbY7

[BiotechTV @BiotechTV]

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰 𝐍𝐢𝐠𝐡𝐭: From Boston, former NIH Director Elias Zerhouni will discuss with BiotechTV the current political and policy environment, and how it is affecting science.

[ModeX Therapeutics @ModeXTx]

Join Us: Jefferies Global Healthcare Conference: OPKO Health, Inc. (OPK):
https://t.co/b3zfxApzdJ

[ModeX Therapeutics @ModeXTx]

Excited to share that Dr. Ronnie Wei, Head of Biologics Discovery and Development, appeared on the @Lonza Podcast to answer questions on what antibodies are, how they are made, and why development in this space has accelerated rapidly. Listen here: https://t.co/odhicKCiJg $OPK

[ModeX Therapeutics @ModeXTx]

#ICYMI Modex was thrilled to be presenting preclinical data on MDX2001, a tetraspecific for targeting solid tumor malignancies today at #SITC24 Details found here: https://t.co/DZmUjonjtg
$OPK

[ModeX Therapeutics @ModeXTx]

ModeX is excited to share information about MDX2001, a novel tetraspecific T cell engager for treatment of advanced solid tumors, at #SITC24 on Nov. 8.

Stop by our posters in the Exhibit Hall to learn more. Details found here: https://t.co/DZmUjonjtg

Tags: $OPK

[ModeX Therapeutics @ModeXTx]

Want to know more about what we do?
Check out our latest publication in Science Translational Medicine, where we show the potential of multispecific antibodies against #COVID-19.
Read more here: https://t.co/aBJ9iLTY7y

[BioCentury @BioCentury]

On the latest #BioCenturyThisWeek podcast: Pediatric PRVs, Biosecure in Congress & @NovoNordisk’s #obesity miss, with @SteveUsdin1 @StephenPHansen @Jeff_Cranmer https://t.co/xBcrBn9BKx

[ModeX Therapeutics @ModeXTx]

Happy International Women's Day! Today we celebrate each of the incredible women at ModeX for their commitment to advancing science and creating new medicines. We're grateful to be able to empower each other on our path to making a difference for patients together. #IWD24

[ModeX Therapeutics @ModeXTx]

Today we announced results from a Phase 1 clinical study of SAR441236, a trispecific antibody for the treatment and prevention of #HIV, at the 2024 Conference on Retroviruses and Opportunistic Infections (#CROI). Learn more: https://t.co/e5ziRUVTBp

[ModeX Therapeutics @ModeXTx]

On #EmployeeAppreciationDay we thank the ModeX team who embody our commitment to creating innovative medicines with their drive for scientific excellence, mission-oriented focus and collaborative spirit. We’re endlessly proud of all the work that you do! #biotechjobs #MakingModeX

[ModeX Therapeutics @ModeXTx]

At ModeX Alicia integrates the team's many skills to progress our goal of developing transformative #multispecific medicines. Managing projects on the oncology team, she treats every day as an opportunity to advance our pipeline.

More on us: https://t.co/Y9TRoTEYyF #biotechjobs

[ModeX Therapeutics @ModeXTx]

By combining multiple antigen-binding sites into a single molecule, our multispecific antibodies are as space-efficient as they can be. Our MSTAR platform simplifies gene expression, allowing for more efficient manufacturing & gene-based antibody delivery. https://t.co/X01WAVceCe

[ModeX Therapeutics @ModeXTx]

Did you know that the HIV virus is one of the most genetically diverse pathogens? Our multispecific HIV antibody, derived from our MSTAR platform, has the potential to potently target more HIV strains than any monospecific antibody. Learn more: https://t.co/X01WAVceCe

[ModeX Therapeutics @ModeXTx]

One of the first people ModeX employees meet is our Head of HR Lana DeAngelis who is passionate about empowering all members of our team to meaningfully contribute to our shared mission.

Learn more about what sets ModeX apart:
https://t.co/Y9TRoTEYyF #Biotechjobs

[ModeX Therapeutics @ModeXTx]

We're creating next generation therapies by uniting the power of multiple medicines into a single molecule. In #cancer, our multispecifics can expand the number of targeted tumor antigens and enable better immune system activation. https://t.co/X01WAVceCe #WorldCancerDay

[ModeX Therapeutics @ModeXTx]

Our President and CEO Gary Nabel spoke at @NIH's Industry Day to discuss how public and private sectors can work together towards a shared goal of saving lives, like our partnership with @BARDA to leverage our multispecific antibody platform MSTAR to combat infectious disease.

[ModeX Therapeutics @ModeXTx]

Our President and CEO Gary Nabel will give the plenary address at @NIH's Industry Day this Thursday, January 18. He will focus on the industry perspective on NIH research being done to target unmet needs across the U.S.

Learn more: https://t.co/KmnImPS2Qk